Local and national advocacy support

Area of Science:

• Immunology
• Healthcare Policy

Background:

• Third-party payors are restricting access to appropriate IgG treatment for patients with primary immunodeficiency disease (PIDD).
• This impacts patient access to necessary therapies and treatment choices.

Purpose of the Study:

• To highlight the need for advocacy to ensure continued access to appropriate IgG treatment for PIDD.
• To emphasize the role of patient and physician organizations in this advocacy.

Main Methods:

• Review of advocacy efforts by patient organizations like the Immune Deficiency Foundation (IDF).
• Discussion of key issues impacting patient access: site of care and product choice.
• Call for local physician advocacy and national efforts by organizations like AAAAI.

Main Results:

• Patient organizations are actively educating stakeholders on access issues.
• Advocacy focuses on patient-centered site of care decisions and product selection.
• Physician and organizational advocacy at local and national levels is crucial.

Conclusions:

• Urgent action is needed to counteract third-party payor restrictions on IgG therapy for PIDD.
• Collaborative advocacy by patients, physicians, and professional organizations is essential for maintaining treatment access.
• Ensuring patient choice in site of care and product is paramount for effective PIDD management.